Research - Keryx Biopharmaceuticals (KERX) announced on Tuesday that a phase 2 study of Zerenex (ferric citrate) in non-dialysis dependent chronic kidney disease (CKD) patients with elevated … Continue Reading
Read nowInsights - On Tuesday at the Transcatheter Cardiovascular Therapeutics conference in San Francisco, Sunshine Heart (SSH) presented updated results from the ongoing OPTIONS-HF European trial testing the … Continue Reading
Read nowLong Ideas - After a negative vote from the FDA’s Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) and repeat signals that the regulatory agency was taking a hardline … Continue Reading
Read nowMost Popular - On Thursday morning, Ziopharm Oncology (ZIOP) priced its recently announced secondary offering at $3.50 per share, a 30% discount to ZIOP’s $4.93 closing price on … Continue Reading
Read nowInsights - A tweet from Adam Feuerstein, senior biotech correspondent for TheStreet.com, piqued our interest last week. The comment caught our eye because of the likelihood that … Continue Reading
Read nowLong Ideas - Early this year, Keryx Biopharmaceuticals (KERX) reported strong Phase III results for its phosphate binder Zerenex (ferric citrate) in dialysis patients, sending the stock from … Continue Reading
Read nowLong Ideas - With the stock down 20% in early morning trading on Friday, October 11, PropThink wrote to PropThink Premium subscribers that Endocyte’s (ECYT) weakness offered another buying opportunity … Continue Reading
Read now
